Safety and Immunogenicity of an AS01-adjuvanted Varicella-zoster Virus Subunit Candidate Vaccine Against Herpes Zoster in Adults >=50 Years of Age
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: An adjuvanted varicella-zoster virus glycoprotein E (gE) subunit vaccine candidate for herpes zoster is in development. In this trial we compared the safety, reactogenicity, and immunogenicity of the vaccine antigen combined with different adjuvant doses. METHODS: This was a phase II, observer-blind, randomized, multinational study. Adults ≥50 years old were randomized 4:4:2:1 to be vaccinated at months 0 and 2 with gE combined with a higher (AS01B) or lower (AS01E) dose adjuvant, unadjuvanted gE, or saline. Following each dose, solicited events were recorded for 7 days and unsolicited adverse events for 30 days. Serious adverse events were collected for 1 year. Cell-mediated and humoral immune responses were assessed at baseline and following each dose. RESULTS: No vaccine-related severe adverse events were reported. Solicited adverse events were generally mild to moderate and transient. For all gE-based vaccines, pain was the most common local symptom and fatigue the most common general symptom. Immune responses were significantly enhanced by AS01B and AS01E compared to unadjuvanted gE and were significantly stronger for gE/AS01B than for gE/AS01E. CONCLUSIONS: AS01 improved the immunogenicity of gE while retaining acceptable safety and reactogenicity profiles. The enhancement of gE-specific cellular and humoral responses was adjuvant dose dependent. CLINICAL TRIALS REGISTRATION: NCT00802464.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The AS01B adjuvant system efficiently induces IgE-specific CD4+ T cells [172] and cell-mediated immunity; antibody responses are also higher compared with those induced by the live-attenuated vaccine [173].”
From Aging of the immune system: Focus on inflammation and vaccination (2016) · cites this paper as [172]
Citations
Cites
A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults
Oxman, M. N., Levin, M. J., Johnson, G. R., Schmader, K. E., Straus, S. E., Gelb, L. D., Arbeit, R. D., Simberkoff, M. S., Gershon, A. A., Davis, L. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051016 · Cited by 2,412
Vaccine Adjuvants: Putting Innate Immunity to Work
Coffman, R. L., Sher, A., & Seder, R. A. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.002 · Cited by 1,924
Arvin, A. M. (1996) · Clinical Microbiology Reviews · doi:10.1128/cmr.9.3.361 · Cited by 1,162
Harpaz, R., Ortega‐Sanchez, I. R., & Seward, J. F. (2008) · PubMed · Cited by 1,037
Kensil, C. R., Patel, U., Lennick, M., & Marciani, D. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.146.2.431 · Cited by 654
Efficacy, Safety, and Tolerability of Herpes Zoster Vaccine in Persons Aged 50-59 Years
Schmader, K. E., Levin, M. J., Gnann, J. W., McNeil, S. A., Vesikari, T., Betts, R. F., Keay, S., Stek, J. E., Bundick, N. D., Su, S.-C., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir970 · Cited by 430
Varicella‐Zoster Virus–Specific Immune Responses in Elderly Recipients of a Herpes Zoster Vaccine
Levin, M. J., Oxman, M. N., Zhang, J. H., Johnson, G. R., Stanley, H., Hayward, A. R., Caulfield, M. J., Irwin, M. R., Smith, J. G., Clair, J., et al. (2008) · The Journal of Infectious Diseases · doi:10.1086/528696 · Cited by 355
Vaccine adjuvant systems: Enhancing the efficacy of sub-unit protein antigens
Perrie, Y., Mohammed, A. R., Kirby, D. J., McNeil, S. E., & Bramwell, V. W. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.04.036 · Cited by 333
Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems
Garçon, N., & Van Mechelen, M. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.29 · Cited by 314
Advances in the understanding of the pathogenesis and epidemiology of herpes zoster
Gershon, A. A., Gershon, M. D., Breuer, J., Levin, M. J., Oaklander, A. L., & Griffiths, P. D. (2010) · Journal of Clinical Virology · doi:10.1016/s1386-6532(10)70002-0 · Cited by 313
Research works printed but not linked: 2
- 2012, Vaccine, 31, 2196
- Chapman, 2008, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control, 57, 1
Cited by
Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
Lal, H., Cunningham, A. L., Godeaux, O., Chlibek, R., Diez-Domingo, J., Hwang, S.-J., Levin, M. J., McElhaney, J. E., Poder, A., Puig-Barberà, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501184 · Cited by 1,454
Self-citationEfficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older
Cunningham, A. L., Lal, H., Kovac, M., Chlibek, R., Hwang, S.-J., Díez-Domingo, J., Godeaux, O., Levin, M. J., McElhaney, J. E., Puig-Barberà, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603800 · Cited by 1,070
Self-citationVaricella zoster virus infection
Gershon, A. A., Breuer, J., Cohen, J. I., Cohrs, R. J., Gershon, M. D., Gilden, D., Grose, C., Hambleton, S., Kennedy, P. G. E., Oxman, M. N., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.16 · Cited by 910
Aging of the immune system: Focus on inflammation and vaccination
Pinti, M., Appay, V., Campisi, J., Frasca, D., Fülöp, T., Sauce, D., Larbi, A., Weinberger, B., & Cossarizza, A. (2016) · European Journal of Immunology · doi:10.1002/eji.201546178 · Cited by 439
Oh, S.-J., Lee, J. K., & Shin, O. S. (2019) · Immune Network · doi:10.4110/in.2019.19.e37 · Cited by 262
Metadata
- Authors
- Chlibek, R., Bayas, J. M., Collins, H., de la Pinta, M. L. R., Ledent, E., Mols, J. F., & Heineman, T. C.
- Affiliations
- Hospital Clínic de Barcelona (ES)
- GlaxoSmithKline (Belgium) (BE)
- GlaxoSmithKline (United States) (US)
- Venue
- Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-07-31
- Volume
- 208
- Issue
- 12
- Pages
- 1953-1961
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2145061830
- Cited by
- 149
- References
- 22
- Citations by year
- 2026: 6 · 2025: 15 · 2024: 14 · 2023: 6 · 2022: 8 · 2021: 15 · 2020: 9 · 2019: 17 · 2018: 16 · 2017: 15 · 2016: 13 · 2015: 11 · 2014: 4
- FWCI
- 6.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Herpesvirus Infections and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Epidemiology › Cytomegalovirus and herpesvirus research
- Keywords
- herpes zoster, varicella-zoster virus, glycoprotein E, subunit vaccine, AS01 adjuvant, vaccine safety, reactogenicity, immunogenicity, older adults, cell-mediated immunity, humoral immune response
- MeSH terms
- Adjuvants, Immunologic, Aged, Antibodies, Viral, Female, Herpes Zoster, Humans, Male, Middle Aged, Herpesvirus 3, Human, Viral Envelope Proteins, CD4-Positive T-Lymphocytes, CD4 Lymphocyte Count, Vaccines, Subunit, Herpes Zoster Vaccine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and Immunogenicity of an AS01-adjuvanted Varicella-zoster Virus Subunit Candidate Vaccine Against Herpes Zoster in Adults >=50 Years of Age. https://app.cochat.ai/papers/10.1093/infdis/jit365
- The paper
- Chlibek, R., Bayas, J. M., Collins, H., de la Pinta, M. L. R., Ledent, E., Mols, J. F., & Heineman, T. C. (2013). Safety and Immunogenicity of an AS01-adjuvanted Varicella-zoster Virus Subunit Candidate Vaccine Against Herpes Zoster in Adults >=50 Years of Age. Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jit365
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.